Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
doi: 10.1002/oby.23930
Economic modeling in patients with obesity and knee osteoarthritis suggests that both semaglutide and tirzepatide would generally be considered cost-effective compared with usual care, with tirzepatide offering the more favorable return on investment once willingness-to-pay thresholds exceed $57,400 per QALY ( 9 Conclusion GLP-1 receptor agonists have expanded the therapeutic discussion in obesity-related knee osteoarthritis by making substantial pharmacologic weight loss achievable for selected patients
The patient portal does in fact list a semaglutide microdose option, just without pricing visible
In our clinic, focusing on the lowest possible dose for weight loss helps to mitigate these side effects
Take semaglutide as directed by your doctor
On the other hand, GLP-1, which comes from a different part of the gut, not only helps with insulin but also has a broader range of benefits, including reducing appetite, slowing down how quickly your stomach empties after eating, and even having protective effects on the brain
US$ 26.88
US$ 28.07
US$ 27.11
US$ 25.35
US$ 24.14
US$ 23.63
